Rhabdomyolysis and HMG-CoA reductase inhibitors

Annals of Pharmacotherapy

Volumn 35, Issue 9, 2001, Pages 1096-1107

  Omar, Mohamed A ^a   Wilson, James P ^a   Cox, Tamara S ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Fibrate; HMG CoA reductase inhibitors; Hyperlipidemia; Myopathy; Rhabdomyolysis; Statins

Indexed keywords

ANTIFUNGAL AGENT; ATORVASTATIN; CERIVASTATIN; CYCLOSPORIN; CYTOCHROME P450; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN;

ACUTE KIDNEY FAILURE; COMPARTMENT SYNDROME; DISEASE COURSE; DRUG POTENTIATION; DYSLIPIDEMIA; HEART DISEASE; HUMAN; KIDNEY METABOLISM; LIPID SOLUBILITY; LIVER METABOLISM; MUSCLE INJURY; MYOPATHY; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SYSTEMIC CIRCULATION;

ADULT; AGED; DRUG INTERACTIONS; FEMALE; HALF-LIFE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; PROGNOSIS; RHABDOMYOLYSIS;

EID: 0034821958     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.10228     Document Type: Review

References (109)

1. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/Tex-CAPS
2. Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS])
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels: The Regression Growth Evaluation Statin Study (REGRESS)
5. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
6. A review of clinical trials comparing HMG-CoA reductase inhibitors
7. Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: A reappraisal
8. Comparative review of the adverse effects of treatments for hyperlipidemia
9. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia
10. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase
11. Drug interactions and the statins
12. Efficacy and tolerability of simvastatin (MK-733)
13. Safety, tolerability, and efficacy of simvastatin and fenofibrate - A multicenter study
14. Current perspectives on statins
15. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors
16. Rhabdomyolysis with simvastatin use
17. Rhabdomyolysis: A review of the literature
18. Rhabdomyolysis: A comprehensive guide
19. Rhabdomyolysis and drug-related myopathies
20. Inflammatory diseases of muscle and other myopathies
21. When exercise goes awry: Exertional rhabdomyolysis
22. Found down: Compartment syndrome, rhabdomyolysis, and renal failure
23. Efficacy and long-term adverse effect pattern of lovastatin
24. Rhabdomyolysis
25. Mechanisms of rhabdomyolysis
26. Hyperlipoproteinemias
27. Disorders of muscle, bone, and connective tissue
28. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
29. Hydrophilicity/lipophilicity: Relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors
30. Fire and forget?" - Pharmacological considerations in coronary care
31. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors: Similarities and differences
32. New insights into the pharmacodynamic and pharmacokinetic properties of statins
33. Clinical pharmacology of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
34. Relative lipophilicities, solubilities, and structural pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin
35. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and Caucasians
36. Treatment of hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage
37. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy
38. Myolysis and acute renal failure in heart transplant patients receiving lovastatin
39. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
40. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients
41. Rhabdomyolysis secondary to lovastatin therapy
42. Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs
43. Rhabdomyolysis and acute renal failure associated with lovastatin
44. Myoglobinuric renal failure due to long-standing lovastatin therapy in a patient with pre-existing chronic renal insufficiency
45. Rhabdomyolysis, acute renal failure and hepatopathy induced by lovastatin monotherapy
46. Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy
47. Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy
48. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis
49. Lovastatin-induced acute rhabdomyolysis
50. Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants
51. Rhabdomyolysis and acute renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibrozil
52. Case of the month: February 1999 - 54-Year-old man with severe muscle weakness
53. Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole
54. Rhabdomyolysis due to combined treatment with lovastatin and cholestyramine
55. Rhabdomyolysis associated with lovastatin and erythromycin use
56. Lovastatin and rhabdomyolysis
57. Multiple organ toxicity from addition of erythromycin to long-term lovastatin therapy
58. Myoglobinuric acute renal failure in a cardiac transplant patient taking lovastatin and cyclosporine
59. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin
60. Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics
61. Severe rhabdomyolysis in a patient receiving lovastatin, danazol, and doxycycline
62. Rhabdomyolysis in a patient treated with lovastatin and cyclosporine
63. Fatal rhabdomyolysis associated with simvastatin in a renal transplant patient
64. Coadministration of itraconazole with hypolipidemic agents may induce rhabdomyolysis in healthy individuals
65. Rhabdomyolysis and simvastatin
66. Acute rhabdomyolysis during treatment with simvastatin (Zocor)
67. Simvastatin-induced rhabdomyolysis followed by a MELAS syndrome
68. Rhabdomyolysis after coronary artery bypass grafting in a patient receiving simvastatin
69. Rhabdomyolysis associated with simvastatin-gemfibrozil therapy
70. Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil
71. Rhabdomyolysis caused by simvastatin in a patient following heart transplantation and cyclosporine therapy
72. Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin
73. Massive rhabdomyolysis and simvastatin
74. Rhabdomyolysis due to simvastatin. [Apropos of a case with review of the literature]
75. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone
76. Rhabdomyolysis and cholestatic hepatitis treated with simvastatin and chlorzoxazone
77. Drug-interaction - Induced rhabdomyolysis
78. Rhabdomyolysis due to interaction of simvastatin with mibefradil
79. Rhabdomyolysis induced by simvastatin and ketoconazole treatment
80. Rhabdomyolysis in patients treated with simvastatin and cyclosporine: Role of hepatic cytochrome P450 enzyme system activity
81. Case report: Rhabdomyolysis induced by mibefradil in a patient treated with cyclosporine and simvastatin
82. Rhabdomyolysis in patients with pre-existing myopathy given lipid lowering drugs
83. Rhabdomyolysis after taking atorvastatin with gemfibrozil
84. Rhabdomyolysis associated with concomitant use of atorvastatin and cyclosporine
85. Rhabdomyolysis and renal failure associated with cerivastatin - Gemfibrozil combination therapy
86. Rhabdomyolysis in a patient receiving the combination of cerivastatin and gemfibrozil
87. Cerivastatin-induced rhabdomyolysis
88. Package insert
89. Package insert
90. Pharmacokinetics of the combination of fluvastatin with gemfibrozil
91. Fluvastatin in familial hypercholesterolemia: A cohort analysis of the response to combination treatment
92. Effects of simvastatin and pravastatin on 6-beta-hydroxycortisol excretion, a potential marker of cytochrome P-450 3A
93. Fibrates and statins in the treatment of hyperlipidemia: An appraisal of their efficacy and safety
94. Long-term efficacy and safety of fenofibrate and a statin in the treatment of combined hyperlipidemia
95. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation
96. Clinical pharmacokinetics of fibric acid derivatives (fibrates)
97. Lovastatin, nicotinic acid, and rhabdomyolysis
98. Myoglobinuric acute renal failure in a cardiac transplant patient taking lovastatin and cyclosporine
99. An overview of the clinical safety profile of atorvastatin (Lipitor), a new HMG-CoA reductase inhibitor
100. Lovastatin-induced rhabdomyolysis
101. Rhabdomyolysis related to ingestion of pravastatin (Vasten)
102. Intraoperative rhabdomyolysis in a patient receiving pravastatin, a 3-hydroxy-3-methyglutaryl coenzyme A (HMG Co A) reductase inhibitor
103. Rhabdomyolysis associated with pravastatin treatment for major depression
104. Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease
105. Acute rhabdomyolysis during combined treatment with pravastatin and gemfibrozil. A case report
106. Rhabdomyolysis caused by pravastatin and type 1 macrocreatine kinase
107. Possible interaction between nefazodone and pravastatin
108. Biologic myolysis during combined fenofibrate-pravastatin therapy